Skip to main content
. 2019 Sep 26;11(10):1442. doi: 10.3390/cancers11101442

Figure 6.

Figure 6

LCC-09 suppresses glioma stem cell (GSC)-related oncogenic and dopaminergic signals while upregulating miR-34a in GBM cells, in vitro (A) Graphical representation of the effect of LCC-09 on the expression of miR22, miR-26b, miR-34a, miR-98, miR-98-3p, miR-142-3p, miR-143, and miR-145 in the TMZ-resistant CD133+ U87MG and D54MG cells. (B) Schema showing LCC-09-relevant targets of miR-34a. (C) The differential effect of miR-34a mimic or inhibitor on the expression level of DRD4, mTOR, Erk1/2, EZH2, and CDK6 proteins in the TMZ-resistant CD133+ U87MG and D54MG cells compared to the sham siRNA-transfected control cells by Western blot assay. (D) Photo-images and histograms of the effect of miR-34a mimic or inhibitor on the neurosphere formation capability of TMZ-resistant CD133+ U87MG and D54MG cells compared to the sham siRNA-transfected control cells. β-actin served as loading control. * p < 0.05, ** p < 0.01, *** p < 0.001; data represent the mean ± SD of experiments performed 4 times in triplicates.